GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » Float Percentage Of Total Shares Outstanding

Biomarin Pharmaceutical (BSP:B1MR34) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 01, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Biomarin Pharmaceutical Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biomarin Pharmaceutical's float shares is 0.00 Mil. Biomarin Pharmaceutical's total shares outstanding is 379.76 Mil. Biomarin Pharmaceutical's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biomarin Pharmaceutical's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biomarin Pharmaceutical's Institutional Ownership is 0.00%.

Biomarin Pharmaceutical Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Biomarin Pharmaceutical's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/379.76
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomarin Pharmaceutical (BSP:B1MR34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
BGNE ALNY RPRX SRPT INCY UTHR TECH BNTX ROIV LEGN OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX OCSE:GMAB
Traded in Other Exchanges
BMRN:USA 1BMRN:Italy BM8:Germany
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
Website
http://www.bmrn.com
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (BSP:B1MR34) Headlines

No Headlines